BioXcel Therapeutics, Inc. BTAI
$1.17
▲ +2.70% 24H
About
BioXcel Therapeutics, Inc. is a biopharmaceutical company that leverages artificial intelligence to develop innovative medicines in neuroscience and immuno-oncology. Its lead product, IGALMI, is a sublingual film approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in …
SectorHealthcare
ExchangeNASDAQ
IndustryDrug Manufacturers - Specialty & Generic
CountryUnited States
Employees37
TickerBTAI
Statistics
Market Cap$31.5M
Revenue (TTM)$642000
Net Income-$69.9M
Net Margin-10887.4%
EPS$-5.73
P/E-0.20
P/S50.40
P/B-0.26
EV/EBITDA-2.33
ROE73.2%
Dividend Yield—
Price$1.17
Data: Twelve Data · Revenue = mcap / P/S